Background {#Sec1}
==========

Coronary artery disease (CAD) is both a leading cause of death and an important health threat in Asian countries as well as in European countries. Markers for CAD in circulation have been sought and identified. However, only a few markers have important clinical implications. Disease biomarkers that can appropriately evaluate the risks for CAD and the early processes of atherosclerosis are desirable. Circulating microRNAs (miRNAs) could be useful candidates as disease biomarkers including cancer. MiRNAs are a class of 20-25 nt single-stranded noncoding RNAs. MiRNAs regulate cellular functions through modulating mRNA degradation and repress translation of mRNAs. MiRNAs regulate the gene expression regarding cell growth, proliferation and apoptosis. MiRNAs are found not only in tissues, but also in body fluids including plasma. Circulating miRNAs remain in stable forms and they are resistant to endogenous RNase. Therefore, the signatures of miRNA in circulation can be useful in diagnosis, therapeutic efficacy and prognosis.

Review {#Sec2}
======

Use of microRNA for biomedical research in thrombosis {#Sec3}
-----------------------------------------------------

Use of microRNA for biomedical research in thrombosis and hemostasis has provided substantial useful information. Matsui et al. evaluated a modified lentiviral delivery strategy \[[@CR1]\]. By incorporating miRNA target sequences they succeeded in facilitated transgene expression in liver and prevented off-target expression in hematopoietic cells. This system effectively restricted transgene expression of coagulation factor VIII (FVIII) to the liver. Level of FVIII in plasma was increased to 9 % of normal level in the hemophilia A mice. Thrombin is thrombogenic and mediates inflammation. Thrombin induces activation and dysfunction of endothelial cells through NF-kB and contributes to formation of arterial thrombus. MiR-181b possesses anti-inflammatory actions and inhibits downstream NF-kB signaling in response to TNF-α. MiR-181b also inhibits upstream NF-kB signaling induced by thrombin \[[@CR2]\].

Dyslipidemia and microRNA {#Sec4}
-------------------------

We measured circulating miRNA in CAD patients. Significant CAD was confirmed by angiography. MiRNA was also measured in patients without CAD \[[@CR3]\]. This study was approved by our institutional ethical committee. Informed consent was obtained from all participants. Dysfunction of endothelium is implicated in early processes of atherosclerosis and thrombosis. Therefore, vascular endothelium-enriched miRNA (miR-126) that can potentially regulate angiogenesis was selected and measured. CAD patients who showed higher levels of myocardial stress marker, brain natriuretic peptide. Their average New York Heart Association class, an index of heart failure, was also higher. The prevalence of hypertension and diabetes were similar between the 2 groups. Patients without CAD showed lower prevalence of dyslipidemia. The lipid profiles were not significantly different between the 2 groups due to anti-hyperlipidemic drugs. Use of aspirin, α- blockers, angiotensin converting enzyme inhibition/angiotensin receptor blockers, statin, long-acting nitrates, insulin, and sulfonyl urea were less frequent in patients without significant CAD. Use of calcium channel blocker was not significantly different between the 2 groups. The levels of miRNA in circulation are relatively low. Thus, approach using microarray may not be sensitive enough to identify miRNAs that can serve as disease biomarkers. Therefore, quantitative RT polymerase chain reaction (qRT-PCR) analysis was utilized on RNA isolated from plasma. There are several plasma miRNAs that were previously reported to have altered levels in type 2 diabetes. We evaluated the candidate miRNAs. The analysis revealed that plasma miR-126 level of patients with CAD was comparable to the level of patients without CAD. This result indicated that miR-126 was not a specific marker for CAD. We noticed that there had been no report that level of miR-126 was influenced by low-density lipoprotein (LDL) cholesterol. The level of miR-126 was significantly decreased in CAD patients who also showed high LDL cholesterol level. The miR-126 level was increased in patients who had risk factors for CAD and high level of LDL cholesterol but did not have CAD. Taken together, our results suggested an association between dysregulated plasma miR-126 and elevated levels of LDL cholesterol in patients who have CAD.

Smoking, endothelial function and microRNA {#Sec5}
------------------------------------------

We also determined microRNA in middle-age male smokers \[[@CR4]\]. Serum cotinine levels, a metabolite marker of nicotine, were inversely correlated with endothelial function expressed as reactive hyperemia peripheral arterial tonometry (RH-PAT) index and high-density lipoprotein (HDL)-cholesterol level, and positively correlated with levels of non-HDL-cholesterol and homeostasis model-insulin resistance (HOMA-IR). The smokers were encouraged to stop smoking. The RH-PAT index was not changed after 8 weeks in all subjects, because only 13 subjects could attain smoking cessation, and PH-PAT did not improve in 17 subjects who could not attain smoking cessation. However, relative percent change of systolic blood pressure was significantly correlated with relative percent change of RH-PAT index. Furthermore, subjects with decreased systolic blood pressure exhibited significantly improved the RH-PAT index. Next, smokers who completely attained smoking cessation were analyzed separately. They indicated increased RH-PAT ratio and plasma miR-126 after 8 weeks of smoking cessation. However, RH-PAT index and expression levels of miR-126 did not show significant difference between subjects who completely attained 8 weeks smoking cessation and subjects who could not attain smoking cessation. These results suggested an association between dysregulated plasma miR-126 level and vascular endothelial damage in middle-age male smokers and favorable effect of smoking cessation on recovery of endothelial function and increase in miR-126 levels.

Platelets and microRNA for development of anti-thrombotic drugs {#Sec6}
---------------------------------------------------------------

Bray et al. investigated the platelet transcriptome in black and white healthy subjects \[[@CR5]\]. Platelet aggregation mediated through PAR4 thrombin receptor was greater in black subjects. Platelets from black subjects expressed lower levels of miR-376c. Lower miR-376c contributed to the higher expression of phosphatidylcholine transfer protein involved in platelet activation through thrombin. These results may imply that a genomic contribution to platelet function may differ by race. This difference may partly explain the lower survival of blacks as compared to whites after myocardial infarction due to coronary atherothrombosis. In the development of agents against thrombosis, one has to consider the effects of race.

Conclusions {#Sec7}
===========

MiRNAs emerged as new biomarkers useful for diagnosis and evaluation of pathophysiology of several atherothrombotic diseases. Standardization in samples, sample processing and storage need care in the laboratory. Technical protocols may become essential for the accurate assessment of miRNAs as biomarkers.
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